Fyremadel Shortage: What Providers and Prescribers Need to Know in 2026

Fyremadel (ganirelix acetate) — the GnRH antagonist widely used in controlled ovarian hyperstimulation (COH) protocols — continues to present intermittent availability challenges for patients and prescribers in 2026. While not currently listed on the FDA or ASHP drug shortage databases, real-world reports from patients and fertility clinics indicate that sourcing Fyremadel at retail pharmacies remains inconsistent.

This briefing provides a concise overview of the current supply landscape, prescribing considerations, alternative agents, cost and access issues, and tools that can help your patients locate Fyremadel when they need it.

Current Supply Status (2026)

The supply situation for Fyremadel/ganirelix acetate in 2026:

• Formal shortage status: Not listed on FDA or ASHP shortage databases
• Retail chain availability: Inconsistent. Many CVS, Walgreens, and Rite Aid locations do not routinely stock Fyremadel
• Specialty pharmacy availability: Generally reliable. Fertility-focused specialty pharmacies and clinic-associated pharmacies maintain more consistent inventory
• Generic availability: Generic ganirelix acetate (Amphastar Pharmaceuticals) is available and helps diversify supply

Clinical Implications of Supply Interruptions

For reproductive endocrinologists and OB/GYNs managing IVF cycles, intermittent Fyremadel availability creates several practical considerations:

• Protocol timing sensitivity: GnRH antagonist protocols depend on daily injections starting mid-stimulation. A gap of even one day can risk a premature LH surge and cycle cancellation. Ensuring medication availability before starting stimulation is critical.
• Patient anxiety: Discovering that Fyremadel is unavailable mid-cycle is highly distressing for fertility patients. Proactive prescribing and pharmacy guidance can prevent this situation.
• Cost as a barrier: Fyremadel retails at $150-$250 per syringe. Patients using 4-6 syringes per cycle face significant out-of-pocket costs, especially since many insurance plans exclude fertility medications.

Therapeutic Substitution: Cetrorelix

Cetrorelix (Cetrotide) is the most straightforward therapeutic substitution for Fyremadel. Both agents:

• Are GnRH antagonists with competitive receptor binding at pituitary gonadotrophs
• Are dosed at 0.25 mg daily subcutaneous injection in the antagonist protocol
• Demonstrate equivalent LH suppression, oocyte yield, and clinical pregnancy rates in head-to-head trials (ESHRE: "no clinically meaningful differences in outcomes between GnRH antagonist preparations")
• Can be switched between mid-cycle without protocol modification

One practical difference: Cetrorelix requires reconstitution of lyophilized powder before injection, while Fyremadel is supplied as a ready-to-use prefilled syringe. Patients switching from Fyremadel to Cetrorelix will need brief instruction on preparation.

Prescribing Recommendations to Mitigate Availability Risk

Consider these prescribing practices to reduce the risk of mid-cycle supply disruptions:

1. Write for generic ganirelix acetate: Generic is bioequivalent, often more available, and significantly less expensive. Unless there is a specific clinical reason to require the brand name, prescribing generic reduces cost and improves access.
2. Confirm pharmacy availability before cycle start: Advise patients to confirm medication availability at their intended pharmacy 7-10 days before their expected FSH start date.
3. Have a backup prescription ready: Consider providing patients with a Cetrorelix prescription at the same time as the Fyremadel prescription, with clear instructions to fill only one unless the first is unavailable.
4. Partner with specialty pharmacies: Establish relationships with fertility-focused specialty pharmacies like Freedom Fertility, MDR Fertility, and Encompass Rx that routinely stock Fyremadel and can provide same-day or next-day shipping.

Tools to Help Your Patients Find Fyremadel

Share medfinder with your patients. medfinder calls pharmacies near the patient to find which ones can fill their Fyremadel prescription and texts them the results. This eliminates the time patients spend calling around and is particularly useful for time-sensitive fertility medications.

Cost Considerations and Patient Support Programs

Cost remains a significant access barrier for many fertility patients. Key resources for providers to share with patients include the Organon Patient Assistance Program (organonhelps.com) for qualifying uninsured patients, and discount programs like GoodRx and SingleCare (which can reduce generic ganirelix to approximately $44 per syringe). For a comprehensive breakdown of all available savings options, see our provider guide to Fyremadel savings programs.